LIFAVYZE
Live / Applied — Suspended — suspension letter mailed (as of 25 Nov 2025)
What this means for you
Not registered yet, but its 27 Jun 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99256149
- Mark type
- Stylized text
- Filed
- 27 Jun 2025
- Attorney of record
- Xiomara Triana
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes
Owner
- Bristol-Myers Squibb Company, Princeton, NJ, US
Prosecution history
- 25 Nov 2025 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 25 Nov 2025 — LETTER OF SUSPENSION E-MAILED
- 25 Nov 2025 — SUSPENSION LETTER WRITTEN
- 17 Nov 2025 — ASSIGNED TO EXAMINER
- 05 Nov 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 27 Jun 2025 — APPLICATION FILING RECEIPT MAILED
- 27 Jun 2025 — NEW APPLICATION ENTERED